Status:
RECRUITING
Staged Kidney Transplantation During Combined Heart/Kidney Transplantation
Lead Sponsor:
Cedars-Sinai Medical Center
Conditions:
Heart Failure
Chronic Kidney Disease
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The primary purpose of this study is to evaluate the safety and efficacy of ex vivo machine perfusion with staged implantation of kidney allografts during combined heart/kidney transplantation.
Detailed Description
Combined heart and kidney transplantation (H/KTx) is the treatment of choice for patients with concomitant heart failure and chronic- or end-stage kidney disease. H/KTx presents a logistical challenge...
Eligibility Criteria
Inclusion
- Adult patients (18 years or older) undergoing combined heart and kidney transplantation at Cedars-Sinai Medical Center.
Exclusion
- Patients who undergo simultaneous heart/kidney transplantation in a single operative event due to medical necessity will be excluded.
- Patients with medical records flagged as "break-the-glass" or "research opt-out" within the center's electronic health record.
Key Trial Info
Start Date :
April 7 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 28 2035
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT06877169
Start Date
April 7 2025
End Date
February 28 2035
Last Update
June 3 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cedars-Sinai Medical Center
Los Angeles, California, United States, 90048